Clinical trials: Asthma Exacerbations
Asthma
A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects
This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who go to the Emergency Department (ED) or their physician's office with an acute bronchospasm.
- Trial name
- NCT02150499
- Testing
- levalbuterol tartrate HFA inhalation aerosol
- Where
- 17 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to…
- Trial name
- NCT02555371
- Testing
- Mepolizumab 100mg
- Where
- 73 sites in United States, Argentina and 12 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan
The purpose of this prospective, epidemiological, cohort study is to evaluate the lung microbiome in stable-state chronic obstructive pulmonary disease (COPD) in Japanese participants
- Trial name
- NCT03957577
- Testing
- Prospective observational cohort study
- Where
- 13 sites in Japan
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Asthma Acute, COPD Exacerbation Acute
Rademikibart IV for Acute Asthma and COPD Exacerbation
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
- Trial name
- NCT07705737
- Testing
- Rademikibart
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Connect Biopharm LLC
Asthma
A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
This study will assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
- Trial name
- NCT05584306
- Testing
- 610 30mg group, 610 100mg group, 610 300mg group
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
Prevention of Asthma Relapse After Discharge From Emergency
The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room
- Trial name
- PARADE (NCT00326053)
- Testing
- Budesonide/formoterol
- Where
- 20 sites in Canada
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Asthma
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
- Trial name
- NCT03137784
- Testing
- NVA237 (glycopyrronium bromide)
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Validation of Structured Light Plethysmography: Asthma
Validation of Structured Light Plethysmography (SLP) in patients with asthma, in patients with acute asthma; an observational study in healthy participants and during patients' clinical investigation of broncho-reversibility in…
- Trial name
- SLPBD (NCT02543333)
- Where
- 2 sites in United Kingdom
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Pneumacare Ltd
Asthma
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose…
- Trial name
- Levante (NCT06529419)
- Testing
- AZD8630, Inhaler
- Where
- 196 sites in United States, Argentina and 21 more
- Volunteers
- 537 people
- Sponsor
- AstraZeneca
Asthma in Children
Leo Study Unstable Asthma
This is a prospective, observational study to investigate the agreement of the Leo device signal derivation with gold standard asthmatic testing in recently exacerbated asthmatic children.
- Trial name
- NCT05308277
- Testing
- Leo device monitoring
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- ResMed
Pneumonia, Bronchiolitis
Diagnosing Respiratory Disease in Children Using Cough Sounds 2
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood acute respiratory disease, including pneumonia, bronchiolitis, asthma/reactive airways disease…
- Conditions
- Pneumonia, Bronchiolitis, Asthma Exacerbation, Croup
- Trial name
- SMARTCOUGH-C-2 (NCT03392363)
- Testing
- Recordings of Infants and Children's Cough Sounds
- Where
- 3 sites in United States
- Volunteers
- 1,470 people
- Sponsor
- ResApp Health Limited
Eosinophilic Asthma
Phase III Long-Term Extension Study With Dexpramipexole
The goal of this clinical trial] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥18 years, on Global Initiative for Asthma (GINA) 2021 [GINA, 2021] Step 4 or 5 therapy and…
- Trial name
- EXHALE-5 (NCT06388889)
- Testing
- Dexpramipexole Dihydrochloride
- Where
- 103 sites in United States, Argentina and 13 more
- Volunteers
- 509 people
- Sponsor
- Areteia Therapeutics
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals